---
title: "AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297516343.md"
description: "On August 31, 2026, AEON Biopharma, Inc. disclosed plans to attend Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference in New York City on September 10, 2026. AEON, trading on NYSE American as AEON, is a biopharmaceutical company working on ABP-450 as a biosimilar to BOTOX for therapeutic purposes in order to secure full-label U.S. market approval. The announcement stated that AEON's management will be conducting face-to-face 1x1 meetings with investors during the conference."
datetime: "2026-08-31T12:02:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297516343.md)
  - [en](https://longbridge.com/en/news/297516343.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297516343.md)
generator: "portal-rs"
---

# AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference

On August 31, 2026, AEON Biopharma, Inc. disclosed plans to attend Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference in New York City on September 10, 2026. AEON, trading on NYSE American as AEON, is a biopharmaceutical company working on ABP-450 as a biosimilar to BOTOX for therapeutic purposes in order to secure full-label U.S. market approval. The announcement stated that AEON's management will be conducting face-to-face 1x1 meetings with investors during the conference.

### Related Stocks

- [AEON.US](https://longbridge.com/en/quote/AEON.US.md)

## Related News & Research

- [AEON Biopharma Q2 net loss narrows on warrant gain; cash runway extended](https://longbridge.com/en/news/295705604.md)
- [13:33 ETAEON Launches Agentic Checkout, Powered by AI Card for Autonomous Commerce](https://longbridge.com/en/news/298063611.md)
- [AEON Biopharma 10% owner Timothy P. Lynch buys 1,150,000 shares for $243,455](https://longbridge.com/en/news/296658850.md)
- [10:30 ETBiosimilars Market worth $70.79 billion by 2036 - Exclusive Report by MarketsandMarkets™](https://longbridge.com/en/news/297801421.md)
- [AEON Biopharma’s Timothy P. Lynch files initial beneficial ownership statement](https://longbridge.com/en/news/296658780.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**